RE:UK seeing near-record Covid cases & three big myths Good warning that we are not out of the woods...not by a long shot.
BA.2 blipping up in Canada now.
Not clear if we will return to PCR testing in a big way (not likely unless/until the hospitals start filling back up to capacity - which is possible)
Many countries are continuing to default to more testing (not just rapid testing, but with the more accurate PCR). But by and large, Canada has fallen off that wagon (to save $, or because Omicron was too transmissive, or because it's now more about ICU capacity than anythign else)
Fall is the next period to worry about - and if it brings with it, a more deadly variant, PCR testing will resume even in Canada. In any event, there will continue to be a base level demand for VTM in Canada, ie.where PCR testing continues (Old Age homes, hospitals, immunocompromised, indigenous, etc.)
The question for MBX...will ON want to stockpile for future needs? Will they prefer to buy a greater % of the VTM output from MBX (i.e. source locally)? Will other provinces be convinced to absorb some of the new Cdn-made capacity? Will the US begin to absorb any excess/left overcapacity output? Will other countries? I don't think that MBX knows yet.
Well aware that MBX is much more than a VTM & Covid related Company. This needs to be proven to the rest of the investment community. Qtr after Qtr of growth will prove that (in Covid and non Covid periods)
Ironically, MBX may (is?) benefit(ing?0) from more Covid headlines, even if PCR testing does not return in a big way. It can work both ways with uneducated investors. Sometimes they help, sometimes they hinder.
* * *
Comments on the SP
I believe the price increase of late, may be somewhat driven by increasing headlines of "the next spike" being just around the corner. The question is, how big?
The AGM was supportive of SP and reassuring to investors. Higher revenues are on the way (the # 1 most important factor IMO)
$ 20- $ 25 for y/e Spet 22, and $ 40M + for 2023. Opening up the possibility of buy-backs, a partnership arrangement on K , and even divdends (although I agree - these can wait for a Co in growth mode).
Re partnership, I would prefer a partnership to "going it alone". They need to "stick to their knitting" and not confuse investors (ie are we a diagnostics Co. / supplier?, or are we a drug developer?)
A partnership, to me, may be preferable to an outright sale of K if there are no buyers willing to pay what it is worth...especially if it looks like in the near term MBX will be throwing off excess cash.
Just some randome thoughts.
Long MBX (regardless of Covid, but especially if there is more to come)
MM